Palatin Technologies

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Palatin Technologies sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Palatin Technologies: 9 sponsored US clinical trials, none currently recruiting.

Palatin Technologies sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypoactive Sexual Desire Disorder, with 1 trials.

Top-decile sponsor footprint

Palatin Technologies ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

NCT06565611
ACTIVE NOT RECRUITING Phase 2

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

NCT05466890
COMPLETED Phase 2

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

NCT05709444
COMPLETED Phase 3

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

NCT05201170
TERMINATED Phase 2

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

NCT04318145
COMPLETED Phase 3

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960
COMPLETED Phase 3

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02333071
COMPLETED Phase 2

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

NCT01382719
COMPLETED Phase 2

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

NCT00425256

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 3

Therapeutic Areas

Hypoactive Sexual Desire Disorder 1
Ulcerative Colitis Flare 1
Ulcerative 1
Ulcerative Colitis Acute 1
Ulcerative Colitis 1
Obesity 1

How the Palatin Technologies early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 6 completed (67%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Hypoactive Sexual Desire Disorder (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Palatin Technologies: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Palatin Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Palatin Technologies4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Palatin Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Palatin Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Palatin Technologies page

9 registered trials is a research-attention snapshot, not an endorsement of Palatin Technologies or any single study.

  • None of Palatin Technologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hypoactive Sexual Desire Disorder is the condition Palatin Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypoactive Sexual Desire Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Palatin Technologies pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.